OraSure (OSUR) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 03, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	1,116,463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		60,648,324

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 76,770	$ 107,959
Restricted cash	1,840	1,831
Short-term investments	83,372	11,160
Accounts receivable, net of allowance for doubtful accounts of $494 and $484	28,099	19,827
Inventories	16,859	11,799
Prepaid expenses	1,189	1,722
Other current assets	1,206	2,143
Total current assets	209,335	156,441
PROPERTY AND EQUIPMENT, net	21,496	20,033
INTANGIBLE ASSETS, net	8,972	10,337
GOODWILL	20,257	18,793
LONG TERM INVESTMENTS	18,290
OTHER ASSETS	3,909	2,331
TOTAL ASSETS	282,259	207,935
CURRENT LIABILITIES:
Accounts payable	9,624	4,633
Deferred revenue	1,186	1,388
Accrued expenses	15,813	11,314
Total current liabilities	26,623	17,335
OTHER LIABILITIES	3,928	2,304
DEFERRED INCOME TAXES	2,194	2,446
COMMITMENTS AND CONTINGENCIES (Note 7)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 60,631 and 56,001 shares issued and outstanding	0	0
Additional paid-in capital	385,978	350,528
Accumulated other comprehensive loss	(9,638)	(14,220)
Accumulated deficit	(126,826)	(150,458)
Total stockholders' equity	249,514	185,850
Total liabilities and stockholders' equity	$ 282,259	$ 207,935

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 494	$ 484
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	60,631,000	56,001,000
Common stock, shares outstanding	60,631,000	56,001,000

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
NET REVENUES:
Product	$ 41,157	$ 25,460	$ 111,771	$ 78,286
Other	1,157	6,791	3,265	14,413
Total revenue	42,314	32,251	115,036	92,699
COST OF PRODUCTS SOLD	17,670	9,576	44,605	28,626
Gross profit	24,644	22,675	70,431	64,073
OPERATING EXPENSES:
Research and development	3,228	3,196	9,536	8,547
Sales and marketing	7,162	6,428	21,541	22,531
General and administrative	6,935	6,907	21,777	19,803
Gain on litigation settlement			(12,500)
Total operating expenses	17,325	16,531	40,354	50,881
Operating income	7,319	6,144	30,077	13,192
OTHER INCOME (EXPENSE)	113	498	676	(34)
Income before income taxes	7,432	6,642	30,753	13,158
INCOME TAX EXPENSE	1,669	400	7,121	634
NET INCOME	$ 5,763	$ 6,242	$ 23,632	$ 12,524
EARNINGS PER SHARE:
BASIC	$ 0.10	$ 0.11	$ 0.40	$ 0.23
DILUTED	$ 0.09	$ 0.11	$ 0.39	$ 0.22
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	60,090	55,653	58,511	55,549
DILUTED	62,172	56,530	60,569	56,273

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
NET INCOME	$ 5,763	$ 6,242	$ 23,632	$ 12,524
OTHER COMPREHENSIVE INCOME
Currency translation adjustments	2,570	(729)	4,882	2,501
Unrealized loss on marketable securities	(245)		(300)
COMPREHENSIVE INCOME	$ 8,088	$ 5,513	$ 28,214	$ 15,025

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
OPERATING ACTIVITIES:
NET INCOME	$ 23,632	$ 12,524
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	5,213	4,438
Depreciation and amortization	4,589	4,152
Unrealized foreign currency loss	(246)	75
Deferred income taxes	(425)	(205)
Changes in assets and liabilities
Accounts receivable	(7,706)	3,818
Inventories	(4,886)	1,236
Prepaid expenses and other assets	1,616	1,186
Accounts payable	4,593	(125)
Deferred revenue	(212)	(1,829)
Accrued expenses and other liabilities	4,193	(90)
Net cash provided by operating activities	30,361	25,180
INVESTING ACTIVITIES:
Purchases of investments	(132,177)	(22,966)
Proceeds from maturities and redemptions of investments	42,613	22,966
Purchases of property and equipment	(3,462)	(3,512)
Net cash used in investing activities	(93,026)	(3,512)
FINANCING ACTIVITIES:
Payments for debt issue costs		(367)
Proceeds from exercise of stock options	31,402	894
Repurchase of common stock	(1,234)	(3,311)
Net cash provided by (used in) financing activities	30,168	(2,784)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	1,317	558
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(31,180)	19,442
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF PERIOD	109,790	94,094
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF PERIOD	78,610	113,536
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	4,317	812
Noncash investing activities (accrued property and equipment purchases)	437	$ 241
Noncash unrealized losses on marketable securities	$ (300)

The Company

The Company	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company We develop, manufacture, market and sell diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products, including immunoassays and other in vitro point-of-care, point-of-care in-home over-the-counter point-of-care

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Results of operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results of operations expected for the full year. Use of Estimates Investments The following is a summary of our available-for-sale securities at September 30, 2017 and December 31, 2016: Amortized Gross Gross Fair Value September 30, 2017 Guaranteed investment certificates $ 16,039 $ — $ — $ 16,039 Corporate bonds 85,923 — (300 ) 85,623 Total available-for-sale securities $ 101,962 $ — $ (300 ) $ 101,662 December 31, 2016 Guaranteed investment certificates $ 11,160 $ — $ — $ 11,160 Total available-for-sale securities $ 11,160 $ — $ — $ 11,160 At September 30, 2017 maturities of our available-for-sale securities were as follows: Less than one year $ 83,582 $ — $ (210 ) $ 83,372 Greater than one year $ 18,380 $ — $ (90 ) $ 18,290 Fair Value of Financial Instruments Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of our available-for-sale securities are measured as Level 1 instruments as of September 30, 2017 and December 31, 2016. Included in cash and cash equivalents at September 30, 2017 and December 31, 2016, was $33,633 and $83,704 invested in government money market funds. These funds hold investments in government securities and are measured as Level 1 instruments. We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2017 and December 31, 2016 was $3,670 and $1,980, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets. In 2017, we purchased certificates of deposit (“CDs”) from a commercial bank. The CDs bear interest at rates ranging from 0.86% to 0.94% and mature periodically through January 15, 2018. The carrying values of the CDs approximate their fair value. These CDs serve as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 7 – Commitments and Contingencies. Inventories September 30, December 31, Raw materials $ 8,252 $ 5,399 Work in process 1,746 1,034 Finished goods 6,861 5,366 $ 16,859 $ 11,799 Property and Equipment Intangible Assets Goodwill We performed our last annual impairment assessment as of July 31, 2017 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of September 30, 2017, we believe no indicators of impairment exist. The increase in goodwill from $18,793 as of December 31, 2016 to $20,257 as of September 30, 2017 is a result of foreign currency translation. Revenue Recognition ® Our net revenues recorded on sales of the OraQuick ® We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. In June 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick ® In June 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick ® ® In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, multi-phased contract includes an initial commitment of $7,000 and options for up to an additional $9,600 to fund the evaluation of additional product enhancements, and clinical and regulatory activities. In May 2017, BARDA exercised an option to provide $2,600 in additional funding for our rapid Zika test. Funding received under this contract is recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the third quarter and first nine months of 2017, $553 and $1,787, respectively, was recognized as other revenue in connection with this grant. During the third quarter and first nine months of 2016, $203 was recognized as other revenue in connection with this grant. In June 2017, we entered into a four-year Charitable Support Agreement with the Bill & Melinda Gates Foundation (“Gates Foundation”) that will enable us to offer our OraQuick ® Customer Sales Returns and Allowances ® ® Deferred Revenue Customer and Vendor Concentrations We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations. Earnings Per Share The computations of basic and diluted earnings per share are as follows: Three Months Nine Months Ended September 30, Ended September 30, 2017 2016 2017 2016 Net income $ 5,763 $ 6,242 $ 23,632 $ 12,524 Weighted average shares of common stock outstanding: Basic 60,090 55,653 58,511 55,549 Dilutive effect of stock options, restricted stock, and performance units 2,082 877 2,058 724 Diluted 62,172 56,530 60,569 56,273 Earnings per share: Basic $ 0.10 $ 0.11 $ 0.40 $ 0.23 Diluted $ 0.09 $ 0.11 $ 0.39 $ 0.22 For the three-month periods ended September 30, 2017 and 2016, outstanding common stock options, unvested restricted stock, and unvested performance units representing 8 and 2,130 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2017 and 2016, outstanding common stock options, unvested restricted stock and unvested performance units representing 238 and 2,837 shares, respectively, were similarly excluded from the computation of diluted earnings per share. Foreign Currency Translation Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange (losses) gains resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $(638) and $84 for the three months ended September 30, 2017 and 2016, respectively. Net foreign exchange losses were $(1,256) and $(564) for the nine months ended September 30, 2017 and 2016, respectively. Accumulated Other Comprehensive Income (Loss) We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at September 30, 2017 consists of $9,338 of currency translation adjustments and $300 of net unrealized losses on marketable securities. Recent Accounting Pronouncements Revenue from Contracts with Customers The FASB allows two adoption methods under ASU 2014-09. We plan to adopt the standard using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of January 1, 2018, recognizing in beginning retained earnings an adjustment for the cumulative effective of the change and providing additional disclosures comparing results to those under the previous accounting standard. Upon initial evaluation, we believe the key changes in the standard that impact our revenue recognition relate to the allocation of the transaction price to performance obligations related to our drug testing kits. This revenue stream amounts to less than 1% of total consolidated revenues. We will continue to evaluate the impact that the adoption of ASU 2014-09 will have on our consolidated financial statements and related disclosures, but do not anticipate the adoption will have a material impact on our financial results. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In March 2017, the FASB issued ASU 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2017
Payables and Accruals [Abstract]
Accrued Expenses	3. Accrued Expenses September 30, December 31, Payroll and related benefits $ 8,684 $ 7,685 Income taxes payable (receivable) 3,303 (39 ) Professional fees 688 982 Royalties 659 715 Other 2,479 1,971 $ 15,813 $ 11,314

Credit Facility

Credit Facility	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Credit Facility	4. Credit Facility On September 30, 2016, we entered into a credit agreement (the “Credit Agreement”) with a commercial bank. The Credit Agreement provides for revolving extensions of credit in an initial aggregate amount of up to $10,000 (inclusive of a letter of credit subfacility of $2,500), with an option to request, prior to the second anniversary of the closing date, that the lender, at its election, provide up to $5,000 of additional revolving commitments. Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets. There were no borrowings outstanding under the Credit Agreement at September 30, 2017 and December 31, 2016. Borrowings under the Credit Agreement are subject to compliance with borrowing base limitations tied to eligibility of accounts receivable. Interest under the Credit Agreement is payable at the London Interbank Offered Rate for one, two, three or six-month loans, as selected by the Company, plus 2.50% per year. The Credit Agreement is subject to an unused line fee of 0.375% per year on the unused portion of the commitment under the Credit Agreement during the revolving period. The maturity date of the Credit Agreement is September 30, 2019. In connection with the Credit Agreement, under certain circumstances, we must comply with a minimum fixed charge coverage ratio of 1.10 to 1.00, measured as of the last day of each fiscal month and for the twelve-fiscal month period ending on such date. As of September 30, 2017 and December 31, 2016, we were in compliance with all applicable covenants in the Credit Agreement.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Stockholders' Equity	5. Stockholders’ Equity Stock-Based Awards We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options or to issue restricted stock, or redeem performance-based restricted stock units, we issue new shares rather than purchase shares on the open market. Total compensation cost related to stock options for the three months ended September 30, 2017 and 2016 was $547 and $646, respectively. Total compensation cost related to stock options for the nine months ended September 30, 2017 and 2016 was $1,554 and $2,033, respectively. Net cash proceeds from the exercise of stock options were $31,402 and $894 for the nine months ended September 30, 2017 and 2016, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was recognized in the consolidated statements of income from stock option exercises during these periods. Compensation cost of $667 and $736 related to restricted shares was recognized during the three months ended September 30, 2017 and 2016, respectively. Compensation cost of $2,022 and $2,137 related to restricted shares was recognized during the nine months ended September 30, 2017 and 2016, respectively. In connection with the vesting of restricted shares during the nine months ended September 30, 2017 and 2016, we purchased and immediately retired 122 and 117 shares with aggregate values of $1,234 and $651, respectively, in satisfaction of minimum tax withholding obligations. Commencing in 2016, we granted performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also remain in our service for three years from the grant date. Performance during the one-year period will be based on a one-year earnings per share target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested. Upon grant of the PSUs, we recognize compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate. Compensation cost of $368 and $114 related to PSUs was recognized during the three months ended September 30, 2017 and 2016, respectively. Compensation cost of $1,637 and $268 related to PSUs was recognized during the nine months ended September 30, 2017 and 2016, respectively. Stock Repurchase Program On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the nine months ended September 30, 2017. During the nine months ended September 30, 2016, we purchased and retired 423 shares of common stock at an average price of $6.29 per share for a total cost of $2,660 under this share purchase agreement.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes During the three and nine months ended September 30, 2017, we recorded tax expense of $1,669 and $7,121, respectively. During the three and nine months ended September 30, 2016, we recorded tax expense of $400 and $634, respectively. Tax expense reflects taxes due to state and Canadian taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of September 30, 2017 relate to the tax effects of the basis difference between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes. Tax expense in the first nine months of 2017 reflects an increase in earnings and additional Canadian taxes due as a result of the $12,500 gain from the settlement of our patent infringement and breach of contract litigation against Ancestry.com DNA LLC and its contract manufacturer. In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate as of both September 30, 2017 and December 31, 2016 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state deferred income tax expense or benefit was recorded for the three and nine-month periods ended September 30, 2017 and 2016. The new accounting guidance under ASU 2016-09 allows for the recognition of excess tax benefits regardless of whether the deduction reduces taxes payable. On January 1, 2017, we recorded a cumulative-effect adjustment to retained earnings of $3,391 to recognize the increase in our net operating loss carryforwards from the cumulative excess tax benefits not recognized in periods prior to January 1, 2017. A corresponding $3,391 increase to our valuation allowance associated with this tax benefit was also recorded to retained earnings thereby resulting in a net impact to retained earnings of $0.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Standby Letters of Credit We established standby letters of credit in the aggregate amount of $1,840, naming international customers as the beneficiaries. These letters of credit were required as a performance guarantee of our obligations under our product supply contracts with those customers and are collateralized by certificates of deposit maintained at a commercial bank. Litigation From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Business Segment Information

Business Segment Information	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Business Segment Information	8. Business Segment Information We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices and medical devices; and our molecular collection systems or “DNAG” business, which primarily consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives other revenues, including exclusivity payments for co-promotion rights and other licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of customers engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, microbiome, animal genetic testing and research. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals. We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated. The following table summarizes operating segment information for the three and nine months ended September 30, 2017 and 2016, and asset information as of September 30, 2017 and December 31, 2016: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net revenues: OSUR $ 23,762 $ 23,924 $ 69,720 $ 69,050 DNAG 18,552 8,327 45,316 23,649 Total $ 42,314 $ 32,251 $ 115,036 $ 92,699 Operating income (loss): OSUR $ (453 ) $ 4,571 $ (235 ) $ 9,098 DNAG 7,772 1,573 30,312 4,094 Total $ 7,319 $ 6,144 $ 30,077 $ 13,192 Depreciation and amortization: OSUR $ 855 $ 688 $ 2,189 $ 2,003 DNAG 843 726 2,400 2,149 Total $ 1,698 $ 1,414 $ 4,589 $ 4,152 Capital expenditures: OSUR $ 1,156 $ 283 $ 2,493 $ 1,406 DNAG 739 500 969 2,106 Total $ 1,895 $ 783 $ 3,462 $ 3,512 September 30, December 31, Total assets: OSUR $ 192,298 $ 151,719 DNAG 89,961 56,216 Total $ 282,259 $ 207,935 The following table represents total net revenues by geographic area, based on the location of the customer: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 United States $ 29,063 $ 26,302 $ 78,871 $ 72,493 Europe 3,204 2,171 8,765 9,006 Other regions 10,047 3,778 27,400 11,200 $ 42,314 $ 32,251 $ 115,036 $ 92,699 The following table represents total long-lived assets by geographic area: September 30, December 31, United States $ 16,644 $ 15,737 Canada 4,767 4,286 Other regions 85 10 $ 21,496 $ 20,033

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Results of operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results of operations expected for the full year.
Use of Estimates	Use of Estimates
Investments	Investments The following is a summary of our available-for-sale securities at September 30, 2017 and December 31, 2016: Amortized Gross Gross Fair Value September 30, 2017 Guaranteed investment certificates $ 16,039 $ — $ — $ 16,039 Corporate bonds 85,923 — (300 ) 85,623 Total available-for-sale securities $ 101,962 $ — $ (300 ) $ 101,662 December 31, 2016 Guaranteed investment certificates $ 11,160 $ — $ — $ 11,160 Total available-for-sale securities $ 11,160 $ — $ — $ 11,160 At September 30, 2017 maturities of our available-for-sale securities were as follows: Less than one year $ 83,582 $ — $ (210 ) $ 83,372 Greater than one year $ 18,380 $ — $ (90 ) $ 18,290
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of our available-for-sale securities are measured as Level 1 instruments as of September 30, 2017 and December 31, 2016. Included in cash and cash equivalents at September 30, 2017 and December 31, 2016, was $33,633 and $83,704 invested in government money market funds. These funds hold investments in government securities and are measured as Level 1 instruments. We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2017 and December 31, 2016 was $3,670 and $1,980, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets. In 2017, we purchased certificates of deposit (“CDs”) from a commercial bank. The CDs bear interest at rates ranging from 0.86% to 0.94% and mature periodically through January 15, 2018. The carrying values of the CDs approximate their fair value. These CDs serve as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 7 – Commitments and Contingencies.
Inventories	Inventories September 30, December 31, Raw materials $ 8,252 $ 5,399 Work in process 1,746 1,034 Finished goods 6,861 5,366 $ 16,859 $ 11,799
Property and Equipment	Property and Equipment
Intangible Assets	Intangible Assets
Goodwill	Goodwill We performed our last annual impairment assessment as of July 31, 2017 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of September 30, 2017, we believe no indicators of impairment exist. The increase in goodwill from $18,793 as of December 31, 2016 to $20,257 as of September 30, 2017 is a result of foreign currency translation.
Revenue Recognition	Revenue Recognition ® Our net revenues recorded on sales of the OraQuick ® We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. In June 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick ® In June 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick ® ® In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, multi-phased contract includes an initial commitment of $7,000 and options for up to an additional $9,600 to fund the evaluation of additional product enhancements, and clinical and regulatory activities. In May 2017, BARDA exercised an option to provide $2,600 in additional funding for our rapid Zika test. Funding received under this contract is recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the third quarter and first nine months of 2017, $553 and $1,787, respectively, was recognized as other revenue in connection with this grant. During the third quarter and first nine months of 2016, $203 was recognized as other revenue in connection with this grant. In June 2017, we entered into a four-year Charitable Support Agreement with the Bill & Melinda Gates Foundation (“Gates Foundation”) that will enable us to offer our OraQuick ® .
Customer Sales Returns and Allowances	Customer Sales Returns and Allowances ® ®
Deferred Revenue	Deferred Revenue
Customer and Vendor Concentrations	Customer and Vendor Concentrations We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
Earnings Per Share	Earnings Per Share The computations of basic and diluted earnings per share are as follows: Three Months Nine Months Ended September 30, Ended September 30, 2017 2016 2017 2016 Net income $ 5,763 $ 6,242 $ 23,632 $ 12,524 Weighted average shares of common stock outstanding: Basic 60,090 55,653 58,511 55,549 Dilutive effect of stock options, restricted stock, and performance units 2,082 877 2,058 724 Diluted 62,172 56,530 60,569 56,273 Earnings per share: Basic $ 0.10 $ 0.11 $ 0.40 $ 0.23 Diluted $ 0.09 $ 0.11 $ 0.39 $ 0.22 For the three-month periods ended September 30, 2017 and 2016, outstanding common stock options, unvested restricted stock, and unvested performance units representing 8 and 2,130 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2017 and 2016, outstanding common stock options, unvested restricted stock and unvested performance units representing 238 and 2,837 shares, respectively, were similarly excluded from the computation of diluted earnings per share.
Foreign Currency Translation	Foreign Currency Translation Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange (losses) gains resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $(638) and $84 for the three months ended September 30, 2017 and 2016, respectively. Net foreign exchange losses were $(1,256) and $(564) for the nine months ended September 30, 2017 and 2016, respectively.
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) paid-in We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at September 30, 2017 consists of $9,338 of currency translation adjustments and $300 of net unrealized losses on marketable securities.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue from Contracts with Customers The FASB allows two adoption methods under ASU 2014-09. We plan to adopt the standard using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of January 1, 2018, recognizing in beginning retained earnings an adjustment for the cumulative effective of the change and providing additional disclosures comparing results to those under the previous accounting standard. Upon initial evaluation, we believe the key changes in the standard that impact our revenue recognition relate to the allocation of the transaction price to performance obligations related to our drug testing kits. This revenue stream amounts to less than 1% of total consolidated revenues. We will continue to evaluate the impact that the adoption of ASU 2014-09 will have on our consolidated financial statements and related disclosures, but do not anticipate the adoption will have a material impact on our financial results. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In March 2017, the FASB issued ASU 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Available-for-sale Securities	The following is a summary of our available-for-sale securities at September 30, 2017 and December 31, 2016: Amortized Gross Gross Fair Value September 30, 2017 Guaranteed investment certificates $ 16,039 $ — $ — $ 16,039 Corporate bonds 85,923 — (300 ) 85,623 Total available-for-sale securities $ 101,962 $ — $ (300 ) $ 101,662 December 31, 2016 Guaranteed investment certificates $ 11,160 $ — $ — $ 11,160 Total available-for-sale securities $ 11,160 $ — $ — $ 11,160 At September 30, 2017 maturities of our available-for-sale securities were as follows: Less than one year $ 83,582 $ — $ (210 ) $ 83,372 Greater than one year $ 18,380 $ — $ (90 ) $ 18,290
Schedule of Inventories	Inventories are stated at the lower of cost or net realizable value determined on a first-in, first-out basis and are comprised of the following: September 30, December 31, Raw materials $ 8,252 $ 5,399 Work in process 1,746 1,034 Finished goods 6,861 5,366 $ 16,859 $ 11,799
Computations of Basic and Diluted Earnings Per Share	The computations of basic and diluted earnings per share are as follows: Three Months Nine Months Ended September 30, Ended September 30, 2017 2016 2017 2016 Net income $ 5,763 $ 6,242 $ 23,632 $ 12,524 Weighted average shares of common stock outstanding: Basic 60,090 55,653 58,511 55,549 Dilutive effect of stock options, restricted stock, and performance units 2,082 877 2,058 724 Diluted 62,172 56,530 60,569 56,273 Earnings per share: Basic $ 0.10 $ 0.11 $ 0.40 $ 0.23 Diluted $ 0.09 $ 0.11 $ 0.39 $ 0.22

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	September 30, December 31, Payroll and related benefits $ 8,684 $ 7,685 Income taxes payable (receivable) 3,303 (39 ) Professional fees 688 982 Royalties 659 715 Other 2,479 1,971 $ 15,813 $ 11,314

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Summary of Operating Segment and Asset Information	The following table summarizes operating segment information for the three and nine months ended September 30, 2017 and 2016, and asset information as of September 30, 2017 and December 31, 2016: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net revenues: OSUR $ 23,762 $ 23,924 $ 69,720 $ 69,050 DNAG 18,552 8,327 45,316 23,649 Total $ 42,314 $ 32,251 $ 115,036 $ 92,699 Operating income (loss): OSUR $ (453 ) $ 4,571 $ (235 ) $ 9,098 DNAG 7,772 1,573 30,312 4,094 Total $ 7,319 $ 6,144 $ 30,077 $ 13,192 Depreciation and amortization: OSUR $ 855 $ 688 $ 2,189 $ 2,003 DNAG 843 726 2,400 2,149 Total $ 1,698 $ 1,414 $ 4,589 $ 4,152 Capital expenditures: OSUR $ 1,156 $ 283 $ 2,493 $ 1,406 DNAG 739 500 969 2,106 Total $ 1,895 $ 783 $ 3,462 $ 3,512 September 30, December 31, Total assets: OSUR $ 192,298 $ 151,719 DNAG 89,961 56,216 Total $ 282,259 $ 207,935
Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area	The following table represents total net revenues by geographic area, based on the location of the customer: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 United States $ 29,063 $ 26,302 $ 78,871 $ 72,493 Europe 3,204 2,171 8,765 9,006 Other regions 10,047 3,778 27,400 11,200 $ 42,314 $ 32,251 $ 115,036 $ 92,699 The following table represents total long-lived assets by geographic area: September 30, December 31, United States $ 16,644 $ 15,737 Canada 4,767 4,286 Other regions 85 10 $ 21,496 $ 20,033

Summary of Significant Accoun19

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 101,962	$ 11,160
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(300)
Fair Value	101,662	11,160
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	16,039	11,160
Gross Unrealized Gains	0	0
Fair Value	16,039	$ 11,160
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	85,923
Gross Unrealized Gains	0
Gross Unrealized Losses	(300)
Fair Value	85,623
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	83,582
Gross Unrealized Gains	0
Gross Unrealized Losses	(210)
Fair Value	83,372
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	18,380
Gross Unrealized Gains	0
Gross Unrealized Losses	(90)
Fair Value	$ 18,290

Summary of Significant Accoun20

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Thousands	Dec. 31, 2016USD ($)	Jul. 31, 2017USD ($)	Jun. 30, 2017USD ($)Country	May 31, 2017USD ($)	Aug. 31, 2016USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Sep. 30, 2017USD ($)Suppliershares	Sep. 30, 2016USD ($)shares	Sep. 30, 2016	Sep. 30, 2017USD ($)Suppliershares	Sep. 30, 2016USD ($)shares	Dec. 31, 2016USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 107,959,000							$ 76,770,000			$ 76,770,000		$ 107,959,000
Fair value of plan assets	1,980,000							3,670,000			3,670,000		1,980,000
Accumulated depreciation of property and equipment	36,067,000							38,689,000			38,689,000		36,067,000
Intangible Assets, Net	10,337,000							8,972,000			8,972,000		10,337,000
Intangible Assets, Accumulated Amortization											1,984,000
Intangible Assets, Foreign currency translation gains											619,000
Accumulated amortization of intangible assets	15,197,000							18,129,000			18,129,000		15,197,000
Amount of goodwill at period end	18,793,000							20,257,000			20,257,000		18,793,000
Revenue recognized								0	$ 6,114,000		0	$ 12,837,000
Maximum value of grant revenue from clinical and regulatory activities					$ 16,600,000		$ 10,400,000
Initial grant revenue from clinical and regulatory activities					7,000,000		1,800,000
Remaining grant revenue from clinical and regulatory activities					$ 9,600,000		$ 8,600,000
Period of grant					6 years		3 years
Additional contract revenue from clinical and regulatory activities		$ 1,330,000		$ 2,600,000		$ 7,200,000
Contract revenues from clinical and regulatory activities								553,000	203,000		1,787,000	203,000
Reserve for sales return and allowances											186,000		217,000
Deferred revenue	1,388,000							1,186,000			1,186,000		1,388,000
Net foreign exchange (losses) gains								(638,000)	$ 84,000		(1,256,000)	$ (564,000)
Accumulated foreign currency adjustments included in other comprehensive loss amounted								9,338,000			9,338,000
Unrealized loss on marketable securities								(245,000)			(300,000)
Ora Quick HIV Self Test [Member] | Bill & Melinda Gates Foundation [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Charitable support agreement term			4 years
Number of countries in which products are sold | Country			50
Maximum amount of funding over the agreement period			$ 20,000,000
Funding received per year			$ 6,000,000
Support payments recognized in product revenue								458,000			458,000
Support payments recognized in other revenue								218,000			$ 218,000
Charitable support agreement commencement date											2017-06
Money Market Fund [Member] | Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	83,704,000							$ 33,633,000			$ 33,633,000		83,704,000
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation | shares								8	2,130		238	2,837
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	$ 1,388,000							$ 1,186,000			$ 1,186,000		$ 1,388,000
AbbVie [Member] | Collaborative Arrangement Co-promotion [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Expiration date of rights agreement											Dec. 31, 2016
Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk											21.00%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	15.00%										14.00%
Customer Two [Member] | Net Consolidated Revenue [Member] | Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk								25.00%	19.00%	14.00%	19.00%
Customer Three [Member] | Net Consolidated Revenue [Member] | Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk								11.00%			10.00%
Purchase obligation								$ 4,000,000			$ 4,000,000
Other [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract revenues from clinical and regulatory activities								$ 386,000	$ 474,000		$ 1,260,000	$ 1,373,000
Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Certificates of deposit maturity date											Jan. 15, 2018
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets											15 years
Maximum [Member] | Net Consolidated Revenue [Member] | Revenue from Rights Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk											1.00%
Maximum [Member] | Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets											40 years
Maximum [Member] | Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets											10 years
Maximum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets											10 years
Maximum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets											10 years
Maximum [Member] | Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit											0.94%
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets											7 years
Minimum [Member] | Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets											20 years
Minimum [Member] | Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets											2 years
Minimum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets											2 years
Minimum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets											2 years
Minimum [Member] | Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit											0.86%
DNA Genotek [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of third-party suppliers to manufacture DNAG's products | Supplier								2			2

Summary of Significant Accoun21

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventory, Net [Abstract]
Raw materials	$ 8,252	$ 5,399
Work in process	1,746	1,034
Finished goods	6,861	5,366
Inventories	$ 16,859	$ 11,799

Summary of Significant Accoun22

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
NET INCOME	$ 5,763	$ 6,242	$ 23,632	$ 12,524
Weighted average shares of common stock outstanding:
BASIC	60,090	55,653	58,511	55,549
Dilutive effect of stock options, restricted stock, and performance units	2,082	877	2,058	724
Diluted	62,172	56,530	60,569	56,273
BASIC	$ 0.10	$ 0.11	$ 0.40	$ 0.23
DILUTED	$ 0.09	$ 0.11	$ 0.39	$ 0.22

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 8,684	$ 7,685
Income taxes payable (receivable)	3,303	(39)
Professional fees	688	982
Royalties	659	715
Other	2,479	1,971
Accrued Expenses, Total	$ 15,813	$ 11,314

Credit Facility - Additional In

Credit Facility - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 10,000,000
Line of credit facility, collateral	Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
Borrowings	$ 0	$ 0
Unused capacity commitment fee	0.375%
Maturity date of credit facility	Sep. 30, 2019
Maximum [Member]
Line of Credit Facility [Line Items]
Additional revolving commitments	$ 5,000,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Minimum fixed charge coverage ratio	110.00%
Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Line of credit, interest rate	2.50%
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 2,500,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options			$ 31,402,000	$ 894,000
Income tax benefit realized from stock option exercises during period			0	0
Total compensation cost			$ 5,213,000	$ 4,438,000
Amount share repurchase program of common shares					$ 25,000,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired			0	423
Average price of common stock		$ 6.29		$ 6.29
Total cost of common stock purchased and retired				$ 2,660,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options			$ 31,402,000	894,000
Total compensation cost	$ 547,000	$ 646,000	1,554,000	2,033,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	667,000	736,000	$ 2,022,000	$ 2,137,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations			122,000	117,000
Restricted shares of common stock and stock options, aggregate values			$ 1,234,000	$ 651,000
Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 368,000	$ 114,000	$ 1,637,000	$ 268,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	Jan. 01, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Taxes [Line Items]
INCOME TAX EXPENSE		$ 1,669,000	$ 400,000	$ 7,121,000	$ 634,000
Gain from settlement of litigation against Ancestry.com DNA LLC				12,500,000
U.S. federal or state deferred income tax expense or benefits		$ 0	$ 0	$ 0	$ 0
Accounting Standards Update Two Thousand Sixteen Zero Nine [Member]
Income Taxes [Line Items]
Cumulative-effect adjustment to retained earnings	$ 3,391,000
Net impact of cumulative-effect adjustment to retained earnings	0
Accounting Standards Update Two Thousand Sixteen Zero Nine [Member] | Valuation Allowance, Operating Loss Carryforwards [Member]
Income Taxes [Line Items]
Cumulative-effect adjustment to retained earnings	$ 3,391,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Sep. 30, 2017USD ($)
Standby Letters of Credit [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Standby letters of credit	$ 1,840

Business Segment Information -

Business Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2017Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information 29

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Segment Reporting Information [Line Items]
Net revenues	$ 42,314	$ 32,251	$ 115,036	$ 92,699
Operating income (loss)	7,319	6,144	30,077	13,192
Depreciation and amortization	1,698	1,414	4,589	4,152
Capital expenditures	1,895	783	3,462	3,512
Total assets	282,259		282,259		$ 207,935
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues	23,762	23,924	69,720	69,050
Operating income (loss)	(453)	4,571	(235)	9,098
Depreciation and amortization	855	688	2,189	2,003
Capital expenditures	1,156	283	2,493	1,406
Total assets	192,298		192,298		151,719
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues	18,552	8,327	45,316	23,649
Operating income (loss)	7,772	1,573	30,312	4,094
Depreciation and amortization	843	726	2,400	2,149
Capital expenditures	739	$ 500	969	$ 2,106
Total assets	$ 89,961		$ 89,961		$ 56,216

Business Segment Information 30

Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 42,314	$ 32,251	$ 115,036	$ 92,699
Long-lived assets	21,496		21,496		$ 20,033
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	29,063	26,302	78,871	72,493
Long-lived assets	16,644		16,644		15,737
Europe [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	3,204	2,171	8,765	9,006
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	10,047	$ 3,778	27,400	$ 11,200
Long-lived assets	85		85		10
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 4,767		$ 4,767		$ 4,286